The Bid & Ask

Quotations, Dispatches, and the Daily Tape

Thursday, August 13, 2026

Subject of the day

RGEN

Concerning the House

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

United States · www.repligen.com

The Long Run

FY 2011–2025 · 15 years

LineLatestCAGRTrend
Revenue$32.45M+7.2%
Gross profit$39.98M+55.2%
Operating income$47.70M+33.0%
Net income$35.60M+29.7%
Cash from ops$113.92M+51.5%
Quotation

$167.49

+1.79 (+1.1%)

52w hi$172.26
52w lo$102.87
Vol751.07K
As ofAug 13
The Verdict

Hold

Our score +0.08

Short+0.21
Medium+0.19
Long-0.41

computed 2026-08-13

By the Numbers

Repligen Corporation

Healthcare · Medical Instruments & Supplies

Market cap$9.45B
Enterprise value$9.23B
Trailing P/E229.44x
Forward P/E63.47x
EV / EBITDA64.06x
P / S (ttm)12.04x
Profit margin5.3%
Return on equity2.0%
Revenue growth+11.9%
Earnings growth-65.9%
Debt / equity32.72
Risk Metrics
Beta vs SPX1.39
Corr SPX0.46
Annual vol49.3%
Annual ret+12.3%
Sharpe0.25
Max DD-41.0%

Window: 504 trading days (504 obs)

Layer Breakdown
LayerRawContribution
Fundamental-0.10
Sector+0.12
Technical+0.14
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-08-13

Recent Sessions
DateOpenHighLowCloseVol
Aug 13$167.19$168.37$161.90$167.49751.07K
Aug 12$165.21$166.96$162.36$165.70833.90K
Aug 11$163.41$168.20$161.02$164.77989.30K
Aug 10$163.06$166.43$160.99$163.17770.80K
Aug 7$159.44$164.97$159.44$163.90950.50K